Accepted for Publication: October 7, 2019.
Corresponding Author: Eileen M. O’Reilly, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Office 1021, New York, NY 10065 (oreillye@mskcc.org).
Published Online: February 13, 2020. doi:10.1001/jamaoncol.2019.5963
Author Contributions: Drs Rainone, Singh, and O’Reilly contributed equally to this work. Drs Stadler and O’Reilly had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Rainone, Singh, O’Reilly.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Rainone, Singh, Stadler, O’Reilly.
Critical revision of the manuscript for important intellectual content: All authors.
Obtained funding: O’Reilly.
Administrative, technical, or material support: Rainone, Salo-Mullen, O’Reilly.
Supervision: O’Reilly.
Conflict of Interest Disclosures: Dr Stadler reported that immediate family members hold consulting/advisory roles within the field of ophthalmology with Allergan, Adverum Biotechnologies, Alimera Sciences, Inc, BioMarin Pharmaceuticals, Inc, Fortress Biotech, Inc, Genentech, Inc, Novartis International AG, Optos, Regeneron Pharmaceuticals, Inc, Regenxbio, Inc, and Spark Therapeutics. Dr O’Reilly reported receiving personal fees from Merck & Co and AstraZeneca and grants from AstraZeneca during the conduct of the study and grants from Genentech, Inc, Roche, Bristol-Myers Squibb, Celgene Corporation, MabVax Therapeutics Holdings, Inc, Acta Biologica, and Silenseed, Ltd, as well as personal fees from Polaris Pharmaceuticals, Sobi, Bayer, Targovax, and CytomX outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by Cancer Center Support grant P30 CA-008748-48, David M. Rubenstein Center for Pancreatic Cancer Research (principal investigator, Craig Thompson, MD).
Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
1.Rahib
L , Smith
BD , Aizenberg
R , Rosenzweig
AB , Fleshman
JM , Matrisian
LM . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Cancer Res. 2014;74(11):2913-2921. doi:
10.1158/0008-5472.CAN-14-0155
PubMedGoogle ScholarCrossref 9.Yurgelun
MB , Chittenden
AB , Morales-Oyarvide
V ,
et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Genet Med. 2019;21(1):213-223. doi:
10.1038/s41436-018-0009-5PubMedGoogle ScholarCrossref 12.Hu
C , LaDuca
H , Shimelis
H ,
et al. Multigene hereditary cancer panels reveal high-risk pancreatic cancer susceptibility genes [published online July 25, 2018].
JCO Precis Oncol. doi:
10.1200/PO.17.00291Google Scholar 13.Kurian
AW , Hughes
E , Handorf
EA ,
et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women [published online June 27, 2017].
JCO Precis Oncol. doi:
10.1200/PO.16.00066Google Scholar 17.Mandelker
D , Zhang
L , Kemel
Y ,
et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.
JAMA. 2017;318(9):825-835. doi:
10.1001/jama.2017.11137PubMedGoogle ScholarCrossref 19.Taherian
N , Saam
J , Larson
K ,
et al. Hereditary cancer genetic testing among patients with pancreatic cancer. Paper presented at: American Society for Clinical Oncology Annual Meeting; June 3, 2019; Chicago, IL.
26.Singh
RR , Goldberg
J , Varghese
AM , Yu
KH , Park
W , O’Reilly
EM . Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: a scoping review.
Cancer Treat Rev. 2019;75:27-38. doi:
10.1016/j.ctrv.2019.03.003
PubMedGoogle ScholarCrossref 28.Pishvaian
MJ , Bender
RJ , Halverson
D ,
et al. Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor initiative.
Clin Cancer Res. 2018;24(20):5018-5027. doi:
10.1158/1078-0432.CCR-18-0531
PubMedGoogle Scholar 29.Mandelker
D , Donoghue
M , Talukdar
S ,
et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Ann Oncol. 2019;30(8):1221-1231. doi:
10.1093/annonc/mdz136
PubMedGoogle ScholarCrossref 35.Bellcross
CA , Bedrosian
SR , Daniels
E ,
et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.
Genet Med. 2012;14(1):152-162. doi:
10.1038/gim.0b013e31823375ea
PubMedGoogle ScholarCrossref 37.Resta
N , Pierannunzio
D , Lenato
GM ,
et al; AIFEG. Cancer risk associated with
STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.
Dig Liver Dis. 2013;45(7):606-611. doi:
10.1016/j.dld.2012.12.018
PubMedGoogle ScholarCrossref 38.Schneider
K , Zelley
K , Nichols
KE , Garber
J . Li-Fraumeni syndrome. In: Adam
MP , Ardinger
HH , Pagon
RA ,
et al, eds. GeneReviews. Seattle: University of Washington; June 3, 2013.
41.Sehdev
A , Gbolahan
O , Hancock
BA ,
et al. Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX.
Clin Cancer Res. 2018;24(24):6204-6211. doi:
10.1158/1078-0432.CCR-18-1472PubMedGoogle ScholarCrossref 45.Pishvaian
MJ , Blais
EM , Brody
JR ,
et al. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: results from the Know Your Tumor (KYT) program.
J Clin Oncol. 2019;37(4)(suppl):191-191. doi:
10.1200/JCO.2019.37.4_suppl.191
Google ScholarCrossref 47.de Bono
J , Ramanathan
RK , Mina
L ,
et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline
BRCA1/2 mutations and selected sporadic cancers.
Cancer Discov. 2017;7(6):620-629. doi:
10.1158/2159-8290.CD-16-1250
PubMedGoogle ScholarCrossref 48.Shroff
RT , Hendifar
A , McWilliams
RR ,
et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious
BRCA mutation. [published online May 16, 2018].
JCO Precis Oncol. doi:
10.1200/PO.17.00316Google Scholar 50.O’Reilly
EM , Lee
JW , Lowery
MA ,
et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline
BRCA mutation carriers and wild-type
BRCA pancreatic ductal adenocarcinoma.
Cancer. 2018;124(7):1374-1382. doi:
10.1002/cncr.31218
PubMedGoogle ScholarCrossref 51.Reiss Binder
KA , Mick
R , O’Hara
M ,
et al. A phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in
BRCA1,
BRCA2 or
PALB2 [published online July 2019].
Cancer Res. doi:
10.1158/1538-7445.AM2019-CT234Google Scholar 58.Syngal
S , Brand
RE , Church
JM , Giardiello
FM , Hampel
HL , Burt
RW ; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes.
Am J Gastroenterol. 2015;110(2):223-262. doi:
10.1038/ajg.2014.435
PubMedGoogle ScholarCrossref 61.Chaffee
KG , Oberg
AL , McWilliams
RR ,
et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
Genet Med. 2018;20(1):119-127. doi:
10.1038/gim.2017.85
PubMedGoogle ScholarCrossref 63.Vasen
H , Ibrahim
I , Ponce
CG ,
et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers.
J Clin Oncol. 2016;34(17):2010-2019. doi:
10.1200/JCO.2015.64.0730
PubMedGoogle ScholarCrossref 65.Stoll
K , Kubendran
S , Cohen
SA . The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine.
Am J Med Genet C Semin Med Genet. 2018;178(1):24-37. doi:
10.1002/ajmg.c.31602
PubMedGoogle ScholarCrossref 73.Xiong
HQ , Varadhachary
GR , Blais
JC , Hess
KR , Abbruzzese
JL , Wolff
RA . Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Cancer. 2008;113(8):2046-2052. doi:
10.1002/cncr.23810
PubMedGoogle ScholarCrossref 74.Balmaña
J , Digiovanni
L , Gaddam
P ,
et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing.
J Clin Oncol. 2016;34(34):4071-4078. doi:
10.1200/JCO.2016.68.4316
PubMedGoogle ScholarCrossref 78.Tandy-Connor
S , Guiltinan
J , Krempely
K ,
et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
Genet Med. 2018;20(12):1515-1521. doi:
10.1038/gim.2018.38PubMedGoogle ScholarCrossref